Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

Introduction Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

Atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech recently announced positive topline results from a phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD). The study, ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Deep transcranial magnetic stimulation was safe and effective in treating adolescents and young adults with major depressive ...

The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

Shares of ATAI Life Sciences (NASDAQ:ATAI) skyrocketed 29% on Tuesday after the biotech company and its partner, Beckley ...

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of a planned merger with mental health-focused company Atai Life ...

Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...